LON:OKYO OKYO Pharma (OKYO) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About OKYO Pharma Stock (LON:OKYO) Get OKYO Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume364,142 shsAverage Volume431,999 shsMarket Capitalization£23.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. Read More Receive OKYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OKYO Stock News HeadlinesOKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal painJuly 8, 2026 | finance.yahoo.comOKYO Pharma Secures FDA Backing to Advance Urcosimod into Global Phase 3 Trial for Neuropathic Corneal PainJuly 8, 2026 | tipranks.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing. | Porter & Company (Ad)OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology SymposiumJuly 7, 2026 | markets.businessinsider.comOKYO Pharma Adds European Eye Disease Expert to Advisory Board as Urcosimod Advances in Neuropathic Corneal PainMay 19, 2026 | tipranks.comOKYO Pharma (OKYO) price target increased by 25.00% to 10.20May 14, 2026 | msn.comOKYO Pharma Limited - Ordinary Shares - NewApril 30, 2026 | money.usnews.comOKYO Pharma to Showcase Urcosimod NCP Data at May Ophthalmology Meetings in DenverApril 29, 2026 | tipranks.comSee More Headlines OKYO Stock Analysis - Frequently Asked Questions How do I buy shares of OKYO Pharma? Shares of OKYO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of OKYO Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that OKYO Pharma investors own include Avino Silver & Gold Mines (ASM), AutoZone (AZO), Intel (INTC), TJX Companies (TJX), Aurora Cannabis (ACB), Academy Sports and Outdoors (ASO). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolLON:OKYO CIKN/A Webwww.okyopharma.com Phone44 20 7495 2379FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£6.70 million Net MarginsN/A Pretax MarginN/A Return on Equity-397.13% Return on Assets-154.72% Debt Debt-to-Equity Ratio1.65 Current Ratio0.83 Quick Ratio2.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow28.00 Book ValueGBX (1) per share Price / BookN/AMiscellaneous Outstanding Shares1,660,000,000Free FloatN/AMarket Cap£23.24 million OptionableNot Optionable Beta-0.06 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (LON:OKYO) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | SponsoredPrint this and keep it by your screenEver been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...Profits Run | SponsoredYour money is changingPorter Stansberry - who warned readers about Fannie Mae in 2006, called gold in 2008, and predicted COVID-era ...Porter & Company | SponsoredThe $5 company SpaceX can’t survive withoutThe investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
